INTRODUCTION
Killer cell immunoglobulin-like receptors (KIRs) are a family of transmembrane glycoproteins with activating and inhibitory isoforms; their ligands include the human leukocyte antigen (HLA) class I molecules (1, 2) . KIRs are expressed predominantly on natural killer (NK) cells and are primarily associated with innate NK cell-mediated immunity. However, recent studies have shown that KIRs can also affect adaptive T cell-mediated immunity.
Two distinct routes whereby inhibitory KIRs (iKIRs) affect T cell responses have been described (3, 4) . First, iKIR expression on CD8 ; the frequency of KIR + T cells increases with age and some persistent viral infections (5) (6) (7) (8) (9) . In mice, inhibitory Ly49 receptors (the functional homolog of iKIRs) enhance CD8 + T cell survival (10) . Similarly, in KIR-transgenic mice, ligation of iKIRs on T cells reduces activation-induced death (11, 12) . Furthermore, iKIR expression on human T cells is associated with higher levels of the survival molecule Bcl-2, reduced cell death, and impaired functionality (13) (14) (15) . Second, KIRs indirectly modify the CD8 + T cell response via their expression on NK cells. NK cells regulate T cell immunity by cytokine secretion and killing activated CD4 + and CD8 + T cells; this regulation may be modified by the expression of inhibitory receptors on NK cells (4, 16, 17) . In mice, lymphocytic choriomeningitis virus-specific CD8 + T cell responses are modulated via NK cell-mediated killing of activated CD4 + T cells (18) , and in murine cytomegalovirus infection, interleukin-10 production by NK cells impairs the CD8 + T cell response (19) . In addition, human NK cells can lyse hepatitis B virus-specific CD8 + T cells in vitro (20) .
The clinical relevance of an interaction between iKIRs and CD8 + T cells is difficult to infer from these earlier studies, because it is impossible to determine whether changes in CD8 + T cell lifespan in mice or in vitro alter the course of human disease in vivo. To investigate whether iKIRs have a clinically significant impact on the CD8 + T cell response, our starting point was the well-documented association between certain HLA class I alleles and disease outcome, because this represents compelling evidence that CD8 + T cells are clinically relevant. We reasoned that if KIRs significantly affect the CD8 + T cell response, then KIRs will affect HLA class I disease associations. In a previous study, we validated this approach by showing that KIR2DL2 exaggerates both protective and detrimental HLA class I associations with disease progression in individuals infected with hepatitis C virus (HCV) or human T cell leukemia virus type 1 (HTLV-1) (21) . However, it remains unclear whether this constitutes a generalizable phenomenon that extends to other viruses and iKIRs. Furthermore, the mechanism underlying the effect was not investigated.
In this study, we used epidemiological data from multiple independent cohorts of HIV-1-, HCV-, and HTLV-1-infected individuals; in vitro T cell survival assays; ex vivo analyses of KIR expression; and mathematical modeling of host-virus dynamics. Our data indicate that both two-domain and three-domain iKIRs, together with their HLA class I ligands, enhance the CD8 + T cell response to HIV-1, HTLV-1, and HCV by prolonging CD8 + T cell survival and are a significant determinant of clinical outcome in all three viral infections.
RESULTS
We studied a well-characterized cohort of HIV-1 seroconverters from sub-Saharan Africa who were identified when seronegative and followed under protocol C of the International AIDS Vaccine Initiative (IAVI) (22) (23) (24) . First, we sought to identify KIR-HLA associations that could potentially confound our study. We define a "functional KIR gene" as a KIR gene together with a gene encoding its HLA class I ligand. Both functional KIR3DS1 (KIR3DS1 with the gene encoding its putative ligand HLA-Bw4-80I) and functional KIR3DL1 (KIR3DL1 with the gene for its ligand HLA-Bw4) have previously been associated with good NK cell-mediated control of HIV-1 infection (25) . In the IAVI cohort, the protective effect of functional KIR3DS1, but not functional KIR3DL1, was replicated (table S1). To prevent confounding effects arising from strong linkage disequilibrium between the KIR genes, we therefore excluded all individuals with functional KIR3DS1. As expected, HLA-B*57 was significantly associated with low early set-point viral load (coefficient = −0.42, P = 0.004 and slow progression to low CD4 count (hazard ratio = 0.44, P = 0.02). The coefficient (Coeff) is the change in log 10 [early viral load set point] associated with possession of HLA-B*57, and the hazard (HR) is the relative risk of progression to low CD4 count associated with possession of HLA-B*57.
iKIR genes are associated with an enhancement of the protective effect of HLA-B* 57 To determine whether HLA-B*57 was more protective in the presence of functional KIR2DL2, we stratified the cohort into individuals with and without functional KIR2DL2 and analyzed the protective effect of HLA-B*57 in each stratum. Two definitions of functional KIR2DL2 were considered: (i) strong functional KIR2DL2 (KIR2DL2 with genes encoding its strong HLA-C1 ligand) and (ii) weak functional KIR2DL2 (KIR2DL2 with genes encoding its weaker HLA-C2 ligand). For both early set-point viral load and time to low CD4 count, HLA-B*57 was significantly protective in the stratum with functional KIR2DL2 but weaker and nonsignificant in its absence; additionally, the magnitude of the protection was greater with the stronger ligand ( Fig. 1A and Table 1 ). These differences were not attributable to cohort size because there were fewer HLA-B*57 + individuals in the stratum with functional KIR2DL2 than in the stratum without functional KIR2DL2. We then extended the analysis to other iKIRs with known ligands (KIR2DL1 with HLA-C2 and KIR2DL3 with HLA-C1). Functional KIR3DL1 could not be analyzed because there were no individuals with HLA-B*57 who lacked functional KIR3DL1. iKIRs with disputed ligands were excluded from the analysis. Both functional KIR2DL1 and functional KIR2DL3 enhanced the protective effect of HLA-B*57 on both early set-point viral load and time to low CD4 count ( Fig. 1A and Table 1 ). The odds of seeing this enhancement by chance are P = 2 × 10 −6 (permutation test). Having investigated the effect of the presence or absence of individual functional iKIR, we next investigated the effect of the number of functional iKIRs. For each individual in the cohort, we assigned two numbers: (i) the "count of functional iKIR" (the count of the number of iKIR-ligand pairs) and (ii) an "inhibitory score" (similar to the count but weighted to reflect the strength of iKIR signaling; Supplementary methods). We first stratified the cohort based on the inhibitory score (all cutoffs that gave balanced strata were considered) and analyzed the strength of HLA-B*57-mediated protection in each stratum. Again, we found that the protective effect of HLA-B*57 on both early set-point viral load and progression to low CD4 count was enhanced in the high inhibitory score stratum and that the size of the protective effect increased with the magnitude of the score (Fig. 1, A (table S3) .
To check that the iKIR-associated enhancement we observed was not driven by leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) binding (26) (which was significantly protective in our cohort; table S4) or by functional KIR3DL1 [which was not protective in our cohort (table S1) but has been reported elsewhere (25) ], we included these terms as covariates in our model. In both cases, the conclusions were unchanged (table S5), indicating that functional iKIR enhancement was not attributable to these potentially confounding factors. The conclusions were also unchanged when we included KIR3DL2 with genes for its classical HLA ligands (HLA-A3, HLA-A11, and HLA-B27) or genes for its classical and nonclassical HLA ligands [HLA-A3, HLA-A11, HLA-B27, and HLA-F (27) ] in the count of functional iKIRs and the inhibitory score.
Which iKIR is responsible for the enhancement of

HLA-B*57-mediated protection?
The KIR genes are in strong linkage disequilibrium, so the enhancements of HLA-B*57-mediated protection by functional KIR2DL1, functional KIR2DL2, and functional KIR2DL3 are not independent. Establishing which iKIR gene(s) was associated with the enhancement was difficult because the cohort size limited the power of further substratification. Across the cohort, functional KIR2DL1 and functional KIR2DL2 were both negatively associated with functional KIR2DL3, whereas functional KIR2DL1 and functional KIR2DL2 were unassociated. Given that all three functional iKIRs enhanced HLA-B*57 and none of them were positively associated suggests that more than one functional iKIR was enhancing HLA-B*57-mediated protection (the requirement for ligand makes enhancement via 3 of 16 "absence of a KIR" unlikely). Furthermore, among HLA-B*57 + individuals, both the count of functional iKIRs and the inhibitory score were better predictors of early viral load than any of the individual functional iKIRs, again suggesting that more than one iKIR was enhancing the protective effect of HLA-B*57. Henceforth, because of the difficulty in determining which iKIR(s) was responsible for the enhancement of HLA-B*57 together with the evidence that more than one iKIR was implicated, we focus on the count of iKIRs and the inhibitory score rather than individual iKIR.
Maintenance of the protective effect of HLA-B*57 depends on iKIRs Next, we investigated longitudinal viral load in the IAVI cohort (a total of 5197 person-visits between 0 and 2000 days after infection). The IAVI cohort (n = 461) was stratified into individuals with or without the functional iKIR of interest, into individuals with different inhibitory scores, and into individuals with a low or high count of functional iKIRs. In each stratum, the protective effect of HLA-B*57 on early set-point viral load was analyzed using multivariate linear regression. The coefficients (change in early set-point viral load associated with HLA-B*57) are plotted. It can be seen that the protective effect of HLA-B*57 was enhanced by all three iKIRs, by high inhibitory score, and by high count of iKIRs with a dose effect with inhibitory score. The cohort was stratified in three ways: (i) functional iKIR negative and iKIR positive, (ii) low and high functional iKIR count, or (iii) low and high inhibitory score. In each case, the local nonparametric regression lines were calculated ( Fig. 2A and fig. S2 ). A consistent picture emerged for each of the three functional iKIRs and for both the iKIR count and inhibitory score. In the presence of a strong inhibitory signal (functional iKIR positive or a high inhibitory score/ count), the protective effect of HLA-B*57 on viral load was sustained over time. Conversely, in the absence of a strong inhibitory signal (functional iKIR negative or a low inhibitory score/count), the protective effect of HLA-B*57 on viral load was weak. In the absence of a strong inhibitory signal ( Fig. 2A, left panel) , HLA-B*57 appeared to protect at very early time points after infection, but this protective effect was eroded with time. Bootstrap estimation of the correlation between HLA-B*57-mediated protection and time confirmed this observation: The protective effect of HLA-B*57 decreased significantly more rapidly in people with a low inhibitory score (Fig. 2B ). These findings are consistent with our hypothesis that a strong inhibitory signal enhances T cell survival.
What is the impact of iKIRs on the detrimental effect of
HLA-B*35Px?
In the context of HTLV-1 infection, KIR2DL2 has also been shown to enhance the detrimental effects of the susceptibility allele HLA-B*54 " denotes the strata of individuals with inhibitory score ≤ 2.0, etc. Note that the stratification provided by the count of iKIRs is the same as one of the stratifications provided by inhibitory score. We report both because the count benefits from being a more objective measure (independent of the choice of weight), whereas the inhibitory score benefits from a greater diversity of values, typically allowing for stratification at more than one cutoff. All cutoffs that gave a sufficiently balanced analysis were considered. P < 0.001 ***; P < 0.01 **; P < 0.05 *; P < 0.1 •; P values are two tailed. (21). We therefore investigated the impact of iKIRs on the wellestablished detrimental association between HLA-B*35Px and the outcome of HIV-1 infection (28). In the IAVI cohort, HLA-B*35Px was associated with an increase in set-point viral load (Coeff = +0.35, P = 0.0007), but this effect was not consistently enhanced by iKIRs (table S6) . However, when we studied longitudinal viral dynamics, it could again be seen that the detrimental impact of HLA-B*35Px on viral load was progressively eroded in individuals with a low inhibitory score and maintained in individuals with a high inhibitory score ( fig. S3 ). This observation explains why iKIR enhancement of the HLA-B*35Px effect was not visible in the original outcome measure, early set-point viral load, which focuses on the first 3 to 9 months after infection. Furthermore, bootstrap estimates of the correlation between time and the detrimental effect of HLA-B*35Px showed that the detrimental effect weakened in individuals with a low inhibitory score but was maintained in individuals with a high inhibitory score (P = 6 × 10 −7
A. Outcome: Early viral load set point
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for inhibitory score cutoffs of 2.0, 2.5, and 2.75, respectively; fig. S3 ). HLA-B*35Px did not influence the time to low CD4 count in the IAVI cohort (HR = 1.04, P = 0.8), so we did not investigate the interplay between iKIRs and HLA-B*35Px for this outcome measure.
Results are replicated in independent cohorts
We considered two independent replication cohorts: IAVI-partners and US. showed a trend to be detrimental (Coeff = +0.16, P = 0.06). In both the unpooled and the pooled cohorts, the effects of HLA-B*57 and HLA-B*35Px were enhanced in people with a high inhibitory score (Table 2) . HLA-B*35Px, which only showed a trend for susceptibility in the pooled cohort and nothing in the unpooled cohort, was highly significantly detrimental in people with a high inhibitory score.
IAVI-partners
US
The US is a cohort of 548 HIV-1 + individuals with known seroconversion date: 57.8% of individuals were white, 38.7% were African American, and 3.5% were Hispanic/"Other"; we therefore stratified by ethnicity. Among whites, but not African Americans, both functional KIR3DS1 (KIR3DS1 ) was protective, individuals with functional KIR3DS1 were removed before analysis to give a clean background [cohorts reported in (B), (C), (E), and (G)]. Note that the only balanced stratification provided by the "count of functional iKIRs" (namely, ≤2 versus >2) is the same as the stratification provided by the inhibitory score with a cutoff of 2.0. The inhibitory score has more diversity than the count, and so, typically, more stratifications by inhibitory score than by count are possible. All cutoffs that gave a sufficiently balanced analysis were considered. P < 0.001 ***; P < 0.01 **; P < 0.05 *; P < 0.1 •; P values are two-tailed.
A. IAVI-partners HLA-B*57
Outcome: Log viral load were consistently enhanced by functional iKIRs (Table 2) . On pooling white, Hispanic/Other, and African Americans (with ethnicity as a covariate), the protective effect of HLA-B*57 and the detrimental effect of HLA-B*35Px were still enhanced, although the enhancement of HLA-B*57 appeared weaker ( Table 2 ), suggesting that the iKIR effect on HLA-B*57 was largely driven by the African American population. These findings were replicated when high-expressing KIR3DL1 alleles were included as a covariate (table S7) .
Results across the cohorts, for the different alleles and for longitudinal viral load were consistent. We conclude that in HIV-1 infection in three independent cohorts, the effects of both protective and detrimental HLA alleles on viral load and disease progression are stronger in the presence of genes coding for iKIRs with their ligands.
iKIRs enhance HLA associations with asymptomatic status in HTLV-1 infection
We previously reported that KIR2DL2 enhances HLA class I associations in HTLV-1 infection but found little evidence for enhancement by other iKIRs (21) . In contrast, the findings reported here show that all iKIRs amenable to analysis enhanced HLA-B*57 and HLA-B*35Px disease associations in HIV-1 infection. We therefore reexamined the HTLV-1 data.
We confirmed that, in the HTLV-1-infected Kagoshima cohort, functional KIR2DL2 strongly enhanced the protective effect of HLA-C*08 and the detrimental effect of HLA-B*54 on the odds of the inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Previously, we reported that, unexpectedly, functional KIR2DL2 did not enhance the protective effect of HLA-A*02 (21) . However, we recently found that only HLA-A*02:07, and not the more frequent HLA-A*02:01 and HLA-A*02:06, associates with protection in the Kagoshima cohort (table S8). We therefore repeated the analysis at the level of four-digit HLA resolution. Although individual numbers were low, we found evidence that KIR2DL2 did enhance the protective effect of HLA-A*02:07 (halving the risk of developing HAM/TSP). Investigating the other iKIRs, we found that the low frequency of HLA-C2 precluded a meaningful analysis of functional KIR2DL1 (too few functional KIR2DL1 + individuals) and functional KIR2DL3 (too few functional KIR2DL3 − individuals), explaining why we had not previously seen an effect for these other iKIRs. However, for functional KIR3DL1, both the positive and negative strata were of sufficient size to permit analysis, and there we found good evidence that functional KIR3DL1 enhanced both the detrimental effect of HLA-B*54 and the protective effects of HLA-A*02:07 and HLA-C*08. Furthermore, the effects of HLA-B*54, HLA-A*02:07, and HLA-C*08 were, in each case, strongest in individuals with a high inhibitory score and were weak and nonsignificant in individuals with a low inhibitory score (Table 3) . The high inhibitory score stratum was heavily enriched for people with strong functional KIR2DL2 [P < 10 −14 (cutoff = 1.5), P < 10 −15 (cutoff = 1.75),  2 test], so the KIR2DL2 enhancement and high iKIR score enhancement of HLA-B*54, HLA-A*02:07, and HLA-C*08 are not independent. However, functional KIR3DL1 is not a surrogate for functional KIR2DL2 (P = 0.86,  2 test), so the enhancement due to KIR2DL2 is independent of the enhancement due to KIR3DL1. We conclude that, although most iKIRs cannot be analyzed (due to the low frequency of HLA-C2 alleles in Japan), there is evidence that, independent of KIR2DL2, another iKIR, KIR3DL1 and a high inhibitory score enhance HLA class I disease associations in HTLV-1 infection. (60) . If we amended our definition of functional KIR3DL1 to include these HLA-A alleles, then the conclusions were unchanged with the exception of HLA-C*08, where our conclusion was strengthened (magnitude of enhancement of protective effect of HLA-C*08 in the functional KIR3DL1-positive stratum is greater). All cutoffs that gave a sufficiently balanced analysis were considered. The definitions of "low" and "high" iKIR counts and scores were reduced compared with other cohorts in this study to compensate for lower overall iKIR counts and scores in the Japanese cohort. P < 0.001 ***; P < 0.01 **; P < 0.05 *; P < 0. (table S9) . However, the high inhibitory score stratum was heavily enriched for people with strong functional KIR2DL2 for all three cutoffs considered (P < 2.10 −16 in each case,  2 test), and so the functional KIR2DL2 enhancement and strong iKIR enhancement of HLA-B*57 are not independent. We conclude that functional KIR2DL2 and a high inhibitory score enhance the protective effect of HLA-B*57 in HCV infection, but it is not possible to test whether other iKIRs show the same behavior.
Primary HLA class I associations are unlikely to be attributable to NK cells
In theory, an HLA class I disease association could be attributable to the role of these molecules as recognition targets for either CD8 Materials and table S10 . We found no evidence to suggest that any of the HLA class I associations could be explained by a ligand preference for certain KIRs. This is consistent with existing evidence that these HLA class I associations are attributable to CD8 + T cells (34) (35) (36) (37) (38) (39) . Furthermore, simply considering iKIR-ligand pairs (without also considering the protective or detrimental HLA class I alleles) finds no significant protective or detrimental effect of any individual iKIR-ligand or of the count of functional iKIR or of the inhibitory score in HIV-1, HTLV-1, or HCV (table S2) .
iKIR ligation enhances CD8 + T cell survival in vitro Studies in mice and in vitro have shown that inhibitory NK receptors on T cells reduce activation-induced cell death (10-12). An iKIRmediated enhancement of CD8
+ T cell survival may therefore explain our immunogenetic findings. However, whereas our immunogenetic findings show that the presence of the HLA ligand is crucial ( fig. S1 ), the role of ligand in the in vitro survival studies is less clear. Two studies reported that iKIRs are associated with CD8 + T cell survival independent of ligand (13, 40) , whereas a third study indicated that KIR ligation is required for the increased survival (15) . To clarify and extend this work, we investigated the impact of blocking iKIR ligation on CD8 + T cell survival in vitro. Three iKIR-expressing CD8 + T cell lines were established: two expressing KIR2DL3 and one expressing KIR3DL1 (fig.  S4 ). The lines were cocultured with the HLA class I-deficient B cell line 721:221 (henceforth 221) that was untransfected, transfected to express a noncognate HLA molecule (HLA-B57:01 or HLA-C04:01 in the case of KIR2DL3 and HLA-C03:04 or HLA-C04:01 in the case of KIR3DL1), or transfected to express a cognate HLA molecule (HLA-C03:04 in the case of KIR2DL3 and HLA-B57:01 in the case of KIR3DL1). Activation was induced with staphylococcal enterotoxin E (SEE). T cell survival was quantified in the presence of antibodies that block KIR (GL183 and Dx9) (41) , antibodies that block HLA class I (Dx17) (42) , or an isotype control. The gating strategy is illustrated in fig. S5 . We found that blocking the iKIR-HLA interaction either by blocking iKIR or by blocking HLA class I significantly decreased the count of live T cells compared with isotype control (median decrease, 40 and 48%, respectively; Fig. 3, A and B) . Survival was similarly impaired in the absence of ligand (221 transfected with noncognate HLA or untransfected; median decrease, 57 and 53%, respectively; Fig. 3, A and B) .
Next, we extended this work to primary CD8 + T cells. Peripheral blood mononuclear cells (PBMCs) from three HLA-B*27 + individuals with ankylosing spondylitis, who have a high proportion of PBMCs expressing KIR3DL2 (6), were stimulated with staphylococcal enterotoxin B (SEB). KIR3DL2 binds HLA-B27 homodimers (6) . Survival of KIR3DL2 + CD8 + T cells was quantified in the presence of antibodies that block KIR3DL2 (Dx31), antibodies that block HLA-B27 homodimers [HD6 (43)], or an isotype control ( fig.  S6 ). We found that blocking the iKIR-HLA interaction reduced the count of live KIR3DL2 + CD8 + T cells compared with isotype control (block KIR: median difference, 63%; block HLA: median difference, 50%; Fig. 3C ).
Last, iKIR ligation has been shown to inhibit CD8 + T cell killing under some conditions (44) . To assess this possibility, which could mitigate the biological impact of enhanced survival, we quantified the impact of iKIR ligation on the mobilization of CD107a, a surrogate marker of degranulation. Greater numbers of live CD107a + cells were observed in the presence of a functional KIR-HLA interaction after stimulation of the KIR2DL3-expressing CD8 + T cell line VTE1 with SEE (Fig. 3D) . In summary, KIR ligation enhances the number of viable cells and the number of functional cells both for CD8 + T cell lines and for primary T cells in vitro.
Virus-specific CD8
+ T cells express iKIR ex vivo To probe the relevance of these findings, we quantified the fraction of virus-specific CD8 + T cells that expressed iKIRs (KIR2DL1, KIR2DL2/ L3, KIR3DL1, and KIR3DL2) in PBMCs from HIV-1-positive and HTLV-1-positive donors. We found considerable proportions of iKIR-expressing pentamer + CD8 + T cells in both groups (HIV-1: mean, 27%; HTLV-1: mean, 15%; Fig. 3E + stem cell memory/naïve T cells ( fig. S9 ). We did not investigate iKIR expression on pentamer + CD8 + T cells from HCV-seropositive individuals because the frequency of HCVspecific CD8 + T cells in the blood is known to be extremely low (45, 46) , due in part to T cell homing to the liver (47) . Instead, we investigated the relationship between functional iKIR expression and cell death ex vivo using bulk CD8 + and CD4 + T cells from healthy donors and HCV-seropositive individuals. We found that iKIR + CD8
+ and iKIR + CD4 + T cells were both less likely to stain with annexin V in individuals where the cognate HLA ligand was present (Supplementary Results and fig. S10 ).
Mathematical modeling can explain the enhancement of both protective and detrimental HLA associations
The hypothesis that iKIRs enhance HLA class I disease associations by enhancing T cell survival sounds reasonable, but closer inspection reveals a number of difficulties. First, iKIRs would be expected to increase the survival of all CD8 + T cells, not just those restricted by protective HLA alleles. In an immunogenetic study, a protective HLA effect reflects the difference in viral control between average and protective HLA alleles, so it is not obvious how a nonspecific increase in T cell survival would enhance protective HLA associations. Second, it is difficult to envisage how the same mechanism could also have the opposite effect and enhance detrimental HLA associations. Last, there is evidence that iKIRs can suppress the lytic activity of CD8 + T cells under some conditions (14) (although this was not replicated in our work with CD107a). This raises another question: Is it reasonable to suggest that in people with a high iKIR score, and potentially a higher level of functional inhibition, CD8 + T cell protection is actually enhanced? To address these questions, we constructed a mechanistic mathematical model of host-virus dynamics for HIV-1. In this model, CD8 + T cells restricted by protective HLA class I molecules were assumed to lyse targets more efficiently than average, whereas CD8 + T cells restricted by detrimental HLA class I molecules were assumed to lyse targets less efficiently than average. In the first instance, we assumed that the only effect of iKIRs was to enhance T cell survival; in later analyses, we assumed that iKIRs also impaired CD8 + T cell lysis. We generated 100,000 random parameter combinations by sampling from the physiological range for each parameter (table S11) and solved the system numerically (Fig. 4A) . For each parameter combination, we recorded whether the protective effect (decrease in set-point viral load associated with possession of a protective HLA class I molecule compared with an average HLA class I molecule) was enhanced in people with a high number of functional iKIRs. We found that most of the runs (97%) showed iKIR-mediated enhancement of protective HLA class I associations (Fig. 4B) . Next, we repeated the analysis for detrimental HLA class I molecules. This showed that detrimental HLA class I-associated effects were also enhanced across a wide range of parameter space (Fig. 4C) . Comparison of the region of parameter space where protective HLA class I associations were enhanced and where detrimental HLA class I associations were enhanced showed that there was broad overlap, that is, there exist parameter regions where both protective and detrimental HLA class I associations were simultaneously enhanced. In addition, when iKIRs were assumed to inhibit T cell lysis, enhancement of protective and detrimental HLA class I effects was decreased, but most of the runs still showed enhancement (Fig. 4, D and E) . Further analysis showed that these results were robust to both structural and parametric changes in the model (Supplementary Methods).
To understand how an increase in CD8 + T cell survival can enhance both protective and detrimental HLA class I associations, we simulated viral load as a function of CD8 + T cell lifespan for three representative individuals: one with average HLA class I molecules, one with a protective HLA class I molecule, and one with a detrimental HLA class I molecule (Fig. 4F) . On seeing this figure, the explanation immediately becomes obvious. In the limit, when CD8 + T cell lifespan is very short, it makes little difference whether an individual has average, protective, or detrimental alleles; everyone has a similar viral load independent of their HLA genotype. In an immunogenetic study, this would manifest as an absence of association between either protective or detrimental alleles and outcome. As CD8 + T cell lifespan is increased (e.g., by iKIRs), the "quality" of the CD8 + T cell response becomes important, and a large difference in viral load emerges between people with average, protective, and detrimental HLA class I alleles. In an immunogenetic study, this would manifest as large protective and detrimental effects; that is, as CD8 + T cell lifespan increases, both protective and detrimental effects are enhanced. Although this model does not prove the hypothesis, it does show that the hypothesis predicts our findings and provides a plausible and intuitive explanation for a seemingly contradictory observation.
DISCUSSION
In this study, we conducted an immunogenetic analysis of three independent cohorts of HIV-1-infected individuals to investigate the impact of iKIR genes on well-established HLA class I disease associations. We found that genes for iKIRs consistently enhanced the protective effect of HLA-B*57 and the detrimental effect of HLA-B*35Px on viral load and progression to low CD4 count. The result was critically dependent on the presence of the KIR ligand. A reanalysis of two other persistent viral infections, HCV and HTLV-1, found consistent results: all four HLA class I associations studied were enhanced in people with a high inhibitory score. We previously reported this effect as an enhancement associated with one particular iKIR (KIR2DL2) (21) . In HCV infection, enhanced HLA class I associations were detected for individuals with KIR2DL2 and individuals with a high inhibitory score, but it was impossible to determine which effect was the driver. However, in HTLV-1 infection, new data made it possible to show that, independent of KIR2DL2, another iKIR (functional KIR3DL1) enhanced both protective and detrimental HLA class I disease associations. The probability of seeing this result by chance is P = 10 −16 ; furthermore, the HIV-1 findings were replicated in two independent cohorts. Collectively, these data suggest that all iKIRs behave in a similar manner and that KIR2DL2 is not functionally unique [although its prevalence and distribution make its effects easier to detect in some cohorts-a hypothesis we suggested previously (21) ]. The iKIRs are closely related, being the product of gene duplication (48) , so it is gratifying that we find a unifying picture in which all iKIRs enhance HLA class I associations in a similar fashion.
We investigated the underlying mechanism using three approaches: (i) analysis of the duration of HLA class I-mediated effects in the HIV-1-infected cohort, (ii) in vitro survival assays combined with ex vivo KIR expression analysis, and (iii) mathematical modeling. In the HIV-1 cohort, the phenomenon of iKIR-mediated enhancement appears to be related to the longevity of the CD8 + T cell response, because both the HLA-B*57 protective effect and the HLA-B*35Px detrimental effect were eroded over time in individuals with a low inhibitory score but were maintained in individuals with a high inhibitory score; the difference in rates between these two groups was consistently highly significant. In vitro, we found that blocking the KIR-HLA interaction significantly reduced cultured and primary T cell survival and functional CD107a + T cell survival after activation with superantigen. In addition, the presence of the KIR ligand was associated with a decrease in annexin V binding on CD4 + and CD8 + T cells expressing iKIR directly ex vivo. We also found substantial to the presence of iKIRs), then the quality of the CD8 + T cell response becomes more important, and so differences between protective, average, and detrimental HLA alleles become more apparent; that is, both protective and detrimental effects are enhanced.
Our conclusions are that iKIRs enhance HLA class I associations and that this can be explained by an increase in CD8 + T cell survival in the presence of functional iKIRs. A number of ways in which iKIRs can increase CD8 + T cell survival have been described. These can be broadly divided into "direct" (iKIRs on T cells affect T cell lifespan) and "indirect" (iKIRs on other cell populations, e.g., NK cells, affect T cell lifespan); these pathways are summarized in fig. S11 . Our finding that, in vitro, iKIR expression on CD8 + T cells is directly associated with increased survival does not preclude a role for iKIR on NK cells in indirectly enhancing CD8 + T cell survival. Both effects may be occurring and increasing CD8 + T cell survival, and both are consistent with our immunogenetic analysis, the longitudinal study, and the mathematical modeling.
The iKIR-ligand binding groups that we use in our definition of "functional iKIR" are simplistic. Incomplete knowledge of how different alleles and different peptides affect binding and signaling precludes a more sophisticated definition. Nevertheless, these simple groupings have proved very powerful in other studies (25, 29, 31, 33, 49, 50) . With the definition of inhibitory score used, we saw clear and reproducible results. This suggests that the inhibitory score is a meaningful metric (the odds of seeing all the results by chance is <10 −23 ). The score is used only to split the cohorts in half, so second-order changes to the calculation of the score will not necessarily change the results; we found that our conclusions were robust to quite dramatic changes to the score (e.g., whether KIR3DL2 with classical class I ligands was included). This is because a person's score can change by a large amount, and they will remain in the same strata. Whether we simply count KIR-ligand pairs or use the inhibitory score has little impact on the conclusions. Another limitation of this work is that the survival assays were only conducted in vitro. The strong associations between possession of combinations of iKIR/HLA genes and clinical outcomes such as time to low CD4 count suggest that these effects are important in vivo, but direct in vivo assays were not performed. Murine in vivo assays provide limited information because Ly49 receptors differ considerably from KIR (this includes profound differences in structure and in the pattern of expression on T cells). Human in vivo studies are limited by ethical considerations but would be an important next step in this work.
HCV, HIV-1, and HTLV-1 are all characterized by continuous high-level viral replication and chronic immune activation, which has been associated with CD8 + T cell exhaustion and activationinduced T cell death (51) (52) (53) (54) . Chronic immune cell activation is also associated with increased KIR expression on T cells (5-9, 44, 55) . iKIR "rescuing" of activated CD8 + T cells may be particularly important in this setting. Most KIR-HLA genetic associations are not replicated across viral infections, for example, KIR3DS1 with HLA-Bw4 is protective in the context of HIV-1 but not HTLV-1 (56); this is difficult to understand unless a very strong peptide dependence is postulated. In contrast, we report that all iKIRs enhance HLA class I associations in all three persistent virus infections we have studied (HIV-1, HCV, and HTLV-1), which suggests a universality that is often missing from KIR studies.
The iKIR-HLA receptor-ligand system also has similarities to the programmed death 1 (PD-1)-programmed death ligand 1/2 system. Both iKIR and PD-1 are inhibitory receptors that interfere with proximal T cell receptor signaling and are up-regulated in the context of chronic viral infection and on tumor-infiltrating lymphocytes. PD-1 and iKIR are both expressed on late-stage differentiated memory T cells, typically in a mutually exclusive manner (57) . Blockade or activation of iKIR would thus affect a different population of T cells compared with PD-1 activation/blockade. These observations, combined with the demonstration here that the iKIR-HLA receptorligand system is clinically significant, suggest novel and synergistic targets for therapeutic immune checkpoint blockade.
MATERIALS AND METHODS
Study design
The aim of this study was to investigate whether iKIRs have a clinically significant impact on the human CD8 + T cell response. We studied the impact of iKIR genotype on six well-documented HLA class I disease associations in three viral infections (Table 4) in five independent cohorts. The work was extended and interpreted by mechanistic mathematical modeling, in vitro T cell survival assays, and ex vivo analysis of iKIR expression.
Ethics statement
The immunogenetic study was approved by the National Health Service (NHS) Research Ethics Committee (13/WS/0064) and the Imperial College Research Ethics Committee (ICREC_11_1_2). Informed consent was obtained at the study sites from all individuals. For the cellular work, written informed consent was obtained from all participants in accordance with the Declaration of Helsinki. Research was conducted under the governance of the Imperial College Healthcare NHS Trust Tissue Bank, approved by the UK National Research Ethics Service (09/H0606/106 and 15/SC/0089).
Immunogenetic cohorts
IAVI is a prospective cohort of treatment-naïve HIV-1 seroconverters from sub-Saharan Africa, identified and followed under protocol C of the IAVI (22, 58) . Individuals who had both KIR3DS1 and the gene encoding its putative ligand, HLA-Bw4-80I, were excluded from the analysis to eliminate the potentially confounding effects of functional KIR3DS1. The cohort comprised individuals with time to low CD4 count information (n = 491) and individuals with early viral load information (n = 461). IAVI-partners is an HIV-1 seroprevalent cohort (n = 315). US is a cohort of HIV-1 seroconverters (n = 548). Kagoshima is a cohort of HTLV-1-infected individuals (n = 392). HCV comprises four subcohorts of HCV-seropositive individuals (n = 782).
Regression
The impact of genotype on outcome was analyzed using multivariate linear, logistic, and Cox regression in R v3.0.1 (59) . Potentially confounding covariates were identified and included in the analysis (listed in Supplementary Methods). All reported P values are two tailed. In vitro T cell survival CD8 + T cell lines Three iKIR-expressing CD8 + T cell lines were established from the peripheral blood of healthy volunteers ( fig. S4 ). The lines were cocultured with the HLA class I-deficient B cell line 221, either untransfected; transfected to express a noncognate HLA molecule (HLA-B57:01 or HLA-C04:01 in the case of KIR2DL3, and HLA-C03:04 or HLA-C04:01 in the case of KIR3DL1); or transfected to express a cognate HLA molecule (HLA-C03:04 in the case of KIR2DL3, and HLA-B57:01 in the case of KIR3DL1). Cells were activated with superantigen SEE. The count of live T cells at day 5 was enumerated using CountBright Absolute Counting Beads (Invitrogen) in the presence of antibodies to block KIR (GL183 and Dx9) (41), antibodies to block HLA class I (Dx17) (42) , or an isotype control. The gating strategy is illustrated in fig. S5 .
Primary T cells PBMCs from three HLA-B*27
+ individuals with ankylosing spondylitis were stimulated with SEB. Survival of KIR3DL2 + CD4 − T cells was quantified in the presence of isotype controls or antibodies that block KIR3DL2 (Dx31) or homodimeric HLA-B27 (HD6) (43) . Table S1 . Impact of KIR3DS1 and KIR3DL1 in the full IAVI cohort. Table S2 . Influence of individual functional iKIRs, inhibitory score, and count of functional iKIRs alone. Table S3 . Functional iKIRs enhance the protective effect of HLA-B*57, analysis by factor. Table S4 . Impact of LILRB2-HLA class I binding on early viral load set point in IAVI. Table S5 . Functional iKIRs enhance the protective effect of HLA-B*57 on early set-point viral load, even when LILRB2_B binding score and functional KIR3DL1 are included. .  Table S9 . The protective effect of HLA-B*57 on odds of spontaneous clearance of HCV is enhanced with increasing inhibitory scores. Table S10 . Can the HLA class I associations studied be explained by NK cell-mediated effects? Table S11 . Parameter ranges used in the mathematical model of host-pathogen dynamics. Table S12 . Most frequent HLA B-C combinations in the IAVI cohort. Table S13 . Data. References 
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